1995
DOI: 10.1074/jbc.270.7.2897
|View full text |Cite
|
Sign up to set email alerts
|

Potent Stimulation of SH-PTP2 Phosphatase Activity by Simultaneous Occupancy of Both SH2 Domains

Abstract: Src homology 2 (SH2) domains are phosphotyrosine binding modules found within many cytoplasmic proteins. A major function of SH2 domains is to bring about the physical assembly of signaling complexes. We now show that, in addition, simultaneous occupancy of both SH2 domains of the phosphotyrosine phosphatase SH-PTP2 (Syp, PTP 1D, PTP-2C) by a tethered peptide with two IRS-1-derived phosphorylation sites potently stimulates phosphatase activity. The concentration required for activation by the tethered peptide … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

13
203
0

Year Published

1998
1998
2002
2002

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 269 publications
(220 citation statements)
references
References 25 publications
13
203
0
Order By: Relevance
“…Overexpression of a catalytically compromised SHP-2 protein (Rivard et al, 1995) or microinjection of either a GST-fusion protein containing the SH2 domains of SHP-2 or neutralizing antibodies (Roche et al, 1996) inhibited PDGF-induced mitogenicity. It has previously been shown that Tyr1009 in the PDGF breceptor binds to SHP-2 (Kazlauskas et al, 1993), and that the association between the SH2 domains of SHP-2 and its target proteins triggers activation of the phosphatase activity of SHP-2 Pluskey et al, 1995). Simultaneous occupancy of both SH2 domains by phosphopeptides is required for full activation of the phosphatase activity of SHP-2 (Eck et al, 1996;Jackson et al, 1997;Ohnishi et al, 1996;Pluskey et al, 1995).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Overexpression of a catalytically compromised SHP-2 protein (Rivard et al, 1995) or microinjection of either a GST-fusion protein containing the SH2 domains of SHP-2 or neutralizing antibodies (Roche et al, 1996) inhibited PDGF-induced mitogenicity. It has previously been shown that Tyr1009 in the PDGF breceptor binds to SHP-2 (Kazlauskas et al, 1993), and that the association between the SH2 domains of SHP-2 and its target proteins triggers activation of the phosphatase activity of SHP-2 Pluskey et al, 1995). Simultaneous occupancy of both SH2 domains by phosphopeptides is required for full activation of the phosphatase activity of SHP-2 (Eck et al, 1996;Jackson et al, 1997;Ohnishi et al, 1996;Pluskey et al, 1995).…”
Section: Introductionmentioning
confidence: 99%
“…It has previously been shown that Tyr1009 in the PDGF breceptor binds to SHP-2 (Kazlauskas et al, 1993), and that the association between the SH2 domains of SHP-2 and its target proteins triggers activation of the phosphatase activity of SHP-2 Pluskey et al, 1995). Simultaneous occupancy of both SH2 domains by phosphopeptides is required for full activation of the phosphatase activity of SHP-2 (Eck et al, 1996;Jackson et al, 1997;Ohnishi et al, 1996;Pluskey et al, 1995). This suggests that additional autophosphorylation sites in the PDGF b-receptor might contribute to the activation of SHP-2.…”
Section: Introductionmentioning
confidence: 99%
“…SHP-2 binds directly to growth factor receptors, such as those of platelet-derived growth factor receptor and epidermal growth factor (EGF) receptor, and undergoes tyrosine phosphorylation in response to receptor stimulation by ligand Vogel et al, 1993;Matozaki and Kasuga, 1996;Neel and Tonks, 1997). Furthermore, in response to insulin, SHP-2 binds via its SH2 domains to IRS-1, a major substrate for the insulin receptor tyrosine kinase (Sun et al, 1991) and is thereby activated (Kuhne et al, 1993;Matozaki et al, 1995;Pluskey et al, 1995). The expression of a catalytically inactive SHP-2 inhibits insulin-induced activation of RAS and mitogen-activated protein (MAP) kinase (Noguchi et al, 1994;Milarski and Saltiel, 1994;Xiao et al, 1994;Yamauchi et al, 1995) as well as EGF-induced MAP kinase activation (Bennett et al, 1996) and thereby blocks DNA synthesis and cell proliferation.…”
Section: Introductionmentioning
confidence: 99%
“…This enzyme binds to IRS-1 at a speci®c phosphotyrosine residue, and its catalytic activity is increased as a result of this interaction (Pluskey et al, 1995). We and others have previously shown that SHP2 is a required positive mediator of insulin/IGF-I signaling (Xiao et al, 1994;Yamauchi et al, 1995;Milarski and Saltiel, 1994).…”
Section: Microinjection Of Reagents Directed Against Irs-1 and Associmentioning
confidence: 98%